Hybridan Small Cap Feast - 28 Feb 23

28 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec

NetScientific (NSCI) – Corporate – PDS Biotech completes successful meeting with FDA for combination treatment

NetScientific (NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies, reported yesterday (27.02.2023) that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, the successful completion of a Type B meeting with the US Food and Drug Administration (FDA). The meeting clears the way to start a pivotal study of a combination therapy of PDS

NetScientific (NSCI) – PDS Biotech announces exclusive global license agreement

NetScientific Plc (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies. Intraday on Tuesday 3 January, NSCI's portfolio company PDS Biotech (NASDAQ: PDSB) announced licensing of exclusive global rights from Merck KGaA for the tumour targeting IL-12 fusion protein M9241.

WH ireland: NetScientific (NSCI) - Reshaping and strengthening of board continues

NetScientific Plc (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies. Intraday on Monday 12 December, the company announced a number of board level changes, that collectively mark a reshaping and strengthening of NSCI's board with both executive and non-executive changes and appointments.

WH Ireland: NetScientific (NSCI) - PDS Biotech Q3 results – Positive clinical data announced at SITC 2022

NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 14 November (yesterday at 14:50) that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB) had provided financial results for Q3 2022 (to 30 September) together with a business update. PDSB achieved a number of milestones in the year to date in connection with four ongoing Phase II clinical trials for its lead candidate, PDS0101 as well as announci

WH Ireland: NetScientific (NSCI) - PDS Biotech to present data to the Annual Meeting for the Society for Immunotherapy of Cancer

NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 7 November that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), will present clinical data from two Phase II clinical trials of its lead candidate PDS0101 - being developed as a potential treatment for HPV-positive cancers. The data will be presented at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022) being held

NetScientific (NSCI) – EMV Capital invests in domestic heat efficiency company Ventive

NetScientific (NSCI) a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies announces that its venture capital arm EMVC, has led and advised on a £2.5m investment round in Ventive, a commercial stage developer and manufacturer of innovative intelligent building service systems in the UK. EMVC has taken a c 16% equity stake in Ventive in partial payment of fees.

WH Ireland: NetScientific (NSCI) - PDS Biotech – expanded interim data in PDS0101 triple combination

NetScientific (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies. Portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), in which NSCI holds a 4.72% stake, announced on 11 October, expanded interim data from a National Cancer Institute-led Phase II clinical study evaluating PDSB's lead candidate PDS0101 in combination with two Merck owned immune modulating drugs. The c

WH Ireland: NetScientific (NSCI) - PDS Biotech announces positive end-of-phase 2 meeting for lead candidate PDS0101 in combination with KEYTRUDA

NetScientific (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies. Portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), in which NSCI holds a 4.72% stake, announced on 3 October that it had completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for its lead candidate, PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrol

WH Ireland: NetScientific (NSCI) - Interim results – portfolio shows plenty of promise

NetScientific Plc (NSCI) is a holding company that invests, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies. Against a difficult macro backdrop, NSCI continues to evidence progress with investment in both capacity and capability across portfolio companies. In turn, we believe this investment is set to yield growth and asset realisations (note Q-Bot share sale) above and beyond that captured in our profit and cashflow pr

NetScientific is well positioned for a market rebound

We believe that NetScientific PLC (LON:NSCI) is well positioned to benefit from a recovery in the life sciences and technology sectors. The group has a broad portfolio of investments, including many that are generating sales and several others that are in late-stage clinical trials. NSCI raised £1.

WH Ireland: NetScientific (NSCI) - Portfolio company PDS Biotechnology enters $35m debt financing agreement

NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. Portfolio company, NASDAQ-listed PDS Biotechnology (PDSB), in which NSCI holds a 4.72% equity stake, announced a new debt financing agreement on 24 August in partnership with Horizon Technology Finance – for a total of $35m, of which it has drawn down an initial $25m. The full text of the announcement can be found here.

Hybridan Small Cap Feast 16/08/22

Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Unigel Group, intends to join the Aquis Growth Market. Unigel Group is a pioneer in the field of thixotropic gels for the fibre optic cable industry. The Company is also a supplier of laminated steel tapes to the fibre optic cable industry in the US. Thixotropic gels and laminated steel tapes are essential components to the rapidly growing global fibre optic cable market. The Group exports to over 40 count

WH Ireland: NetScientific (NSCI) - Completes the acquisition of 30% of Vortex Biotech Holdings

NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. NSCI confirms that further to its announcement of 6 May 2022, that it completed yesterday its acquisition of a 30 % stake in Vortex - a commercial stage Trans-Atlantic company which has developed and launched the VTX-1 platform servicing the liquid biopsy, cell analytics and oncology markets. The Vortex microfluidics technology captures intact, viable circulating tumo

WHI First Light: Spectra Systems, ARC Minerals, KEFI Gold & Copper, Dekel Agri-vision, NetScientific & LifeSafe Holdings

Spectra, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software, has announced its first commercial sale of a Banknote Disinfection System (BDS) to an Asian central bank. The BDS system, utilising Spectra's patented technology, contributes to the safety of central bank staff who handle banknotes incoming from circulation, which may carry bacterial and viral pathogens. The system is a plug and play technology as it does not req

FY22 in line – focus on core increasing

FY22 results are in line with revised estimates. Management continues to intensify its focus on the growing, profitable and cash generative Point-of-Care and Life Sciences activities, where confidence in the latter opportunity is increasing. We make some modest changes to our forecasts to reflect further streamlining post-period end and point to the strong growth outlook from FY24 onwards. We believe this is being overly discounted by the market and view the shares as being in deep value territo

Clean exit from ADL Health

EKF has announced a clean solution has been found for the non-core Laboratory Testing business ADL Health, selling the business back to one of its management team. Having pared back our estimates for this division in February, we expect no further material impact on earnings from this move. Strategically, we view it as positive, removing a distraction and further re-focussing activities back towards the core established Point-of-Care & Central Labs business and the growing new Life Sciences acti

SHORE CAPITAL - Destiny Pharma plc+ (DEST, House Stock at 30p)

Hybridan Small Cap Feast - 06 Mar 23

6 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objective

LIBERUM: Futura Medical* - Eroxon live in EU, FDA decision now Q2

Hybridan Small Cap Feast - 23 Mar 23

23 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Positive momentum persists

2022 was a pivotal year for NIOX as it moved firmly into sustainable profitability and cash generation. The foundations for a scalable platform are now well-established and the group enters 2023 with strong momentum (revenues in the first two months of the year were +19%). Having upgraded our forecasts following the trading update in January, we push through further EBITDA upgrades on improved margin assumptions. NIOX is a rare asset and fully deserves a premium rating. We stay at Buy, with an i

Tissue Regenix - FY 2022 – a pivotal year to a sustainably profitable business

Tissue Regenix reported full-year results to 31 December in line with its January trading update that indicated it had reached EBITDA profitability in Q4. What was undisclosed then was that it included a $0.45m provision, without which it would have generated an adjusted EBITDA of c.$0.4m in H2, illustrating the positive underlying progression to a profitable and sustainable growth company. The outlook remains positive – new products, new geographies and additional distributors/strategic partner

Morning Note – 27 March 2023

Hybridan Small Cap Feast - 21 Mar 23

21 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Hybridan Small Cap Feast - 24 Mar 23

24 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Morning Note – 21 March 2023

SHORE CAPITAL - Warpaint London+ (W7L, House Stock at 198p)

Destiny Pharma - Positive Phase II data with XF-73 published in medical journal

Destiny Pharma announced the publication of Phase II data with anti-bacterial drug XF-73 nasal gel in the peer-reviewed medical journal, Infection Control & Hospital Epidemiology. The data showed that XF-73 treatment in an 83-patient study resulted in a >99% reduction in nasal Staphylococcus aureus burden (after three applications of nasal gel 24 hours prior to surgery) measured 1 hour prior to cardiac surgery, which was the primary end-point of the study. The data are consistent with previous s

Hybridan Small Cap Feast - 14 Mar 23

14 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv